DP-Cor-1: Evaluation of the Benefit of Exercise Testing for the Diagnosis of Obstruction in the Coronary Arteries of the Heart

Sponsor
Centre Hospitalier Sud Francilien (Other)
Overall Status
Recruiting
CT.gov ID
NCT05140434
Collaborator
(none)
120
1
9
13.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether exercise testing can detect an obstruction in a coronary artery, and, thereby, can avoid performing a coronary imaging in some cases.

Patients with a suspicion of coronary artery disease perform an exercise test on an exercise bike with increasing load. EKG, blood pressure, and other parameters are monitored. Patients benefit also of either a cardiac CT scan or a coronary angiography to establish whether they really have coronary obstruction.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Exercise test
  • Diagnostic Test: Cardiac CT

Detailed Description

Double product DP (product of systolic blood pressure and heart rate) is directly related to the myocardial oxygen consumption (MVO2). Since O2 extraction by the myocyte in maximal at rest, only an increase in coronary blood flow can increase MVO2 during exercise. Therefore, if a coronary stenosis limits the maximal coronary flow, it will limit MVO2 and DP at exercise.

Patients with both an exercise test and a coronary artery imaging (cardiac CT or coronary angiography) within 3 months, are included. DP increase (DP max/DP at rest) is measured during a maximal, symptom-limited exercise on a cycloergometer. DP at rest is measured either before the exercise test, at the end of the recovery period or during a visit to the cardiologist in the 2 months of the test, whichever is the smallest.

The predictive power to detect a significant coronary artery stenosis is assessed by computing a Receiving Operating Characteristic (ROC) curve, its area under the curve, sensitivity, specificity, and decision thresholds.

Number expected: 100-120 Time period of data collection: 1/1/2019 to 3/1/2022

Study Design

Study Type:
Observational
Anticipated Enrollment :
120 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Evaluation of the Predictive Power of Double-product Increase Measured During an Exercise Test for the Prediction of Coronary Stenosis as Diagnosed by Cardiac CT Scan or Coronary Angiography.
Anticipated Study Start Date :
Apr 15, 2022
Anticipated Primary Completion Date :
Jan 15, 2023
Anticipated Study Completion Date :
Jan 15, 2023

Outcome Measures

Primary Outcome Measures

  1. Area Under the ROC curve [at 3 months]

    AUC of the ROC curve defined by DP increase and significant coronary artery stenosis or not

Secondary Outcome Measures

  1. Youden threshold [at 3 months]

    Maximalization of the difference between sensitivity and 1-specificity

  2. ROC for women [at 3 months]

    AUC for women

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Starting betweew 1/1/2019 and 3/1/2022

  • 18 year-old patients or older

  • Patients with both exercise testing and either Cardiac CT or coronary angiography within 3 months

  • Patients informed and not opposing to their participation to the study

Exclusion Criteria:
  • Patients unable to fully understand the information related to the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHARANSONNEY Olivier Corbeil-essonnes Cedex France 91106

Sponsors and Collaborators

  • Centre Hospitalier Sud Francilien

Investigators

  • Principal Investigator: Olivier CHARANSONNEY, MD, Centre Hospitalier Sud Francilien

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Sud Francilien
ClinicalTrials.gov Identifier:
NCT05140434
Other Study ID Numbers:
  • 2021/0054
First Posted:
Dec 1, 2021
Last Update Posted:
Apr 20, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Sud Francilien
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2022